primary cutaneous marginal zone B-cell lymphoma

Summary

primary cutaneous marginal zone B-cell lymphoma (MONDO:0015813) is a cancer. A subtype of indolent primary cutaneous B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary cutaneous marginal zone B-cell lymphoma
Mondo ID	MONDO:0015813
Orphanet	178536
NCIT	C7230
SNOMED CT	404140004
UMLS	C1275321
MedGen	698594
GARD	0020159
Is cancer (heuristic)	yes

Also known as: C-MALT · cutaneous Immunocytoma · marginal zone B cell lymphoma of skin · marginal zone B cell lymphoma of the skin · PCMZL · Primary cutaneous marginal zone B cell lymphoma of mucosa-associated lymphoid tissue · Primary cutaneous marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue · Primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue · salt lymphoma · skin-associated lymphoid tissue lymphoma

Disease family

This is a subtype of indolent primary cutaneous B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › indolent primary cutaneous B-cell lymphoma › primary cutaneous marginal zone B-cell lymphoma

Related subtypes (1): primary cutaneous follicle center lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.